#ASCOGI25

@drtimos.bsky.social

15 hours ago

ASCO GI 2025 SoMe Report.pdf Bitly is dedicated to making the internet a safer place for everyone. Use the site preview above to make sure the link takes you where you expect.

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TRwlYf
@ASCO

#SocialListening #LucidQuest

0 0 0 0

@drtimos.bsky.social

1 week ago

ASCO GI 2025 SoMe Report.pdf Bitly is dedicated to making the internet a safer place for everyone. Use the site preview above to make sure the link takes you where you expect.

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TRmdkC
@ASCO

#SocialListening #LucidQuest

0 0 0 0

@drtimos.bsky.social

2 weeks ago

ASCO GI 2025 SoMe Report.pdf

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TRcFzr
@ASCO

#SocialListening #LucidQuest

1 0 0 0

@drtimos.bsky.social

4 weeks ago

ASCO GI 2025 SoMe Report.pdf Bitly is dedicated to making the internet a safer place for everyone. Use the site preview above to make sure the link takes you where you expect.

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TRQxmX
@ASCO

#SocialListening #LucidQuest

0 0 0 0

@drtimos.bsky.social

1 month ago

ASCO GI 2025 SoMe Report.pdf Bitly is dedicated to making the internet a safer place for everyone. Use the site preview above to make sure the link takes you where you expect.

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TRF805
@ASCO

#SocialListening #LucidQuest

0 0 0 0

@drtimos.bsky.social

1 month ago

ASCO GI 2025 SoMe Report.pdf

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TR4sCY
@ASCO

#SocialListening #LucidQuest

0 0 0 0

@drtimos.bsky.social

1 month ago

ASCO GI 2025 SoMe Report.pdf

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TQvxV7
@ASCO

#SocialListening #LucidQuest

0 0 0 0

@drtimos.bsky.social

2 months ago

ASCO GI 2025 SoMe Report.pdf 403. That’s an error. We're sorry, but you do not have access to this page. That’s all we know.

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TQkJJF
@ASCO

#SocialListening #LucidQuest

0 0 0 0

@drtimos.bsky.social

2 months ago

ASCO GI 2025 SoMe Report.pdf 403. That’s an error. We're sorry, but you do not have access to this page. That’s all we know.

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TQYRN4
@ASCO

#SocialListening #LucidQuest

0 0 0 0

@drtimos.bsky.social

2 months ago

ASCO GI 2025 SoMe Report.pdf Bitly is dedicated to making the internet a safer place for everyone. Use the site preview above to make sure the link takes you where you expect.

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TQPfK2
@ASCO

#SocialListening #LucidQuest

0 0 0 0

@drtimos.bsky.social

2 months ago

ASCO GI 2025 SoMe Report.pdf

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TQFj65
@ASCO

#SocialListening #LucidQuest

0 0 0 0

@drtimos.bsky.social

3 months ago

ASCO GI 2025 SoMe Report.pdf 403. That’s an error. We're sorry, but you do not have access to this page. That’s all we know.

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TQ6Y9Q
@ASCO

#SocialListening #LucidQuest

0 0 0 0

@drtimos.bsky.social

3 months ago

ASCO GI 2025 SoMe Report.pdf Bitly is dedicated to making the internet a safer place for everyone. Use the site preview above to make sure the link takes you where you expect.

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TQ1J0W
@ASCO

#SocialListening #LucidQuest

0 0 0 0

@drtimos.bsky.social

3 months ago

ASCO GI 2025 SoMe Report.pdf Bitly is dedicated to making the internet a safer place for everyone. Use the site preview above to make sure the link takes you where you expect.

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TPv5CQ
@ASCO

#SocialListening #LucidQuest

0 0 0 0

@drtimos.bsky.social

3 months ago

ASCO GI 2025 SoMe Report.pdf

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TPmGw2
@ASCO

#SocialListening #LucidQuest

0 0 0 0

@drtimos.bsky.social

4 months ago

ASCO GI 2025 SoMe Report.pdf Bitly is dedicated to making the internet a safer place for everyone. Use the site preview above to make sure the link takes you where you expect.

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TPd2B0
@ASCO

#SocialListening #LucidQuest

0 0 0 0

@drtimos.bsky.social

4 months ago

ASCO GI 2025 SoMe Report.pdf Bitly is dedicated to making the internet a safer place for everyone. Use the site preview above to make sure the link takes you where you expect.

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TPV8mp
@ASCO

#SocialListening #LucidQuest

0 0 0 0

@drtimos.bsky.social

4 months ago

ASCO GI 2025 SoMe Report.pdf

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TPM0lr
@ASCO

#SocialListening #LucidQuest

0 0 0 0

@drtimos.bsky.social

4 months ago

ASCO GI 2025 SoMe Report.pdf

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TPD1dz
@ASCO

#SocialListening #LucidQuest

0 0 0 0

@drtimos.bsky.social

5 months ago

ASCO GI 2025 SoMe Report.pdf • Social Media Insights at Medical / Scientific Congresses 3 • Our methodology 4 • Key takeaways 5 • Conference-related SM activity over time 6 • Top hashtags used 7 • Top discussion themes 8 • Top Leading Voices 9 • Sentiment Analysis 10 • Most frequently used words and phrases 11 • LucidQuest’s SM Insights’ capabilities 12 • Get in touch 13 The LucidQuest Social Media Insights team monitored approximately 8.1K posts before, during, and after ASCO GI 2025 to identify key hashtags, top discussion themes, top ~1.7K posts, and compiled a list of the top most frequent ones. We leveraged our LQ algorithm, which takes into account both user

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TP4s30
@ASCO

#SocialListening #LucidQuest

0 0 0 0

@drtimos.bsky.social

5 months ago

ASCO GI 2025 SoMe Report.pdf Bitly is dedicated to making the internet a safer place for everyone. Use the site preview above to make sure the link takes you where you expect.

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TNxfmF
@ASCO

#SocialListening #LucidQuest

0 0 0 0

@drtimos.bsky.social

5 months ago

ASCO GI 2025 SoMe Report.pdf Bitly is dedicated to making the internet a safer place for everyone. Use the site preview above to make sure the link takes you where you expect.

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TNpvYV
@ASCO

#SocialListening #LucidQuest

0 0 0 0

@drtimos.bsky.social

5 months ago

ASCO GI 2025 SoMe Report.pdf • Social Media Insights at Medical / Scientific Congresses 3 • Our methodology 4 • Key takeaways 5 • Conference-related SM activity over time 6 • Top hashtags used 7 • Top discussion themes 8 • Top Leading Voices 9 • Sentiment Analysis 10 • Most frequently used words and phrases 11 • LucidQuest’s SM Insights’ capabilities 12 • Get in touch 13 The LucidQuest Social Media Insights team monitored approximately 8.1K posts before, during, and after ASCO GI 2025 to identify key hashtags, top discussion themes, top ~1.7K posts, and compiled a list of the top most frequent ones. We leveraged our LQ algorithm, which takes into account both user

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TNgZZf
@ASCO

#SocialListening #LucidQuest

0 0 0 0

@drtimos.bsky.social

6 months ago

ASCO GI 2025 SoMe Report.pdf Bitly is dedicated to making the internet a safer place for everyone. Use the site preview above to make sure the link takes you where you expect.

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TNX9dP
@ASCO

#SocialListening #LucidQuest

0 0 0 0

@drtimos.bsky.social

6 months ago

ASCO GI 2025 SoMe Report.pdf

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TNN2pb
@ASCO

#SocialListening #LucidQuest

0 0 0 0

@drtimos.bsky.social

6 months ago

ASCO GI 2025 SoMe Report.pdf

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TNDClF
@ASCO

#SocialListening #LucidQuest

0 0 0 0

@drtimos.bsky.social

6 months ago

ASCO GI 2025 SoMe Report.pdf Bitly is dedicated to making the internet a safer place for everyone. Use the site preview above to make sure the link takes you where you expect.

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TN4ly5
@ASCO

#SocialListening #LucidQuest

0 0 0 0

@drtimos.bsky.social

7 months ago

ASCO GI 2025 SoMe Report.pdf Bitly is dedicated to making the internet a safer place for everyone. Use the site preview above to make sure the link takes you where you expect.

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TMxWqz
@ASCO

#SocialListening #LucidQuest

0 0 0 0

@drtimos.bsky.social

7 months ago

ASCO GI 2025 SoMe Report.pdf

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TMnMDg
@ASCO

#SocialListening #LucidQuest

0 0 0 0

@drtimos.bsky.social

7 months ago

ASCO GI 2025 SoMe Report.pdf Bitly is dedicated to making the internet a safer place for everyone. Use the site preview above to make sure the link takes you where you expect.

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TMfkkH
@ASCO

#SocialListening #LucidQuest

0 0 0 0

Posts tagged #ASCOGI25